Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: DNLI Denali Therapeutics Inc. 8-K

Denali shareholders re-elect directors with mixed support; Cook receives 61% approval

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

  • medium

    Director Jennifer Cook re-elected with 61% of votes cast (48% of shares outstanding), notably lower than co-directors Schenkein (74%) and Watts (97%), potentially signaling shareholder concerns about her board service.

  • low

    Executive compensation approved with 94% support (117M for, 7.1M against), reflecting general shareholder satisfaction with pay practices.

  • low

    Ernst & Young ratified as independent auditor for fiscal 2026 with 99.7% approval, indicating strong confidence in auditor selection.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.

Partner

Trade DNLI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify